Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Novo Nordisk
Sort By
Newest First
Sign in
1 / 1
1 / 1
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74
Nov 05, 2024
M&A
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Novo Holdings A/S
PR-M04-22-05
Apr 07, 2022
Expansion
Novo Nordisk Invests in Upgrading and Expanding Production Facilities in Kalundborg
Novo Nordisk
PR-M02-20-NI-013-1753
Feb 11, 2020
Drug Pricing
Novo Nordisk Launching Additional US Insulin Affordability Offerings in January 2020
Novo Nordisk
PA2138
Sep 11, 2019
Sustainability
Novo Nordisk Turns the Switch On Renewable Energy
Emilie Branch
Pharma's Almanac
PAO-M05-19-NI-013
May 10, 2019
Pediatric
Novo Nordisk Files for a Label Update for Fiasp® to the EMA and the FDA Seeking Approval for Use in Children and Adolescents
Novo Nordisk
PR-M03-19-NI-007
Mar 04, 2019
Diabetes
Novo Nordisk to Use Priority Voucher for Diabetes Drug
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M02-19-NI-004
Feb 06, 2019
Acquisition
Ziylo Acquired by Novo Nordisk in Deal That Could Exceed US$800m
Unit DX Incubator
PR-M09-18-NI-069
Sep 24, 2018
Patient Adherence
New Approach by Novo Nordisk Ties Pricing to Patient Behavior
Emilie Branch
Pharma's Almanac
PAO-M04-18-NI-017
Apr 26, 2018
Drug Development
More Good News for Novo Nordisk’s Semaglutide and Weight Loss
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M03-18-NI-024
Mar 23, 2018
Clinical Trials
Novo Nordisk Bags FDA Approval for New Diabetes Treatment
Nice Insight
PAO-M12-17-NI-024
Dec 15, 2017
Drug Development
New Insulin Formulation Improves Mealtime Glycemic Control
Emilie Branch
Pharma's Almanac
PAO-M10-17-NI-011
Oct 10, 2017
